


CLAIMS

5 1 – Organometallic complexes that can be obtained by reacting :

- at least one strontium cation,
- sitosterol or a plant extract containing same,
- at least one mono-, one di- or one triglyceride corresponding to formula (I):



10

in which:

R1 is an acyl moiety of a C14 to C24 fatty acid, saturated or not, linear or branched, a hydrogen atom, or a mono-, di- or tri- galactose or glucose,

-R2 is an acyl moiety of a C2 to C18 fatty acid, linear or branched, saturated or not,

15 -R3 is an acyl moiety of a C14 to C24 fatty acid, saturated or not, linear or branched, or a hydrogen atom.

2 – Complexes according to claim 1, wherein at least one of the groups R1 or R3 in formula (I) hereinabove is composed of an acyl moiety of oleic acid (C18: 1[cis]-9).

20

3 – Complexes according to either one of claims 1 or 2, in which R₂ has an unsaturated bond, preferably it represents an oleic acid or one of the double bond positional isomers (cis-6, 7, 9, 11, 12 and 13) or one of the geometric isomers thereof.

25 4 – Complexes according to either one of claims 1 or 2, in which R₂ represents an acetyl group.

5- Complexes according to any one of claims 1 to 4, in which R₃ in formula (I) represents the hydrogen atom.

30

6- Complexes according to any one of claims 1 to 5, in which the diglyceride is obtained by isolation from olive oil or an oil rich in oleic acid, or an oil fraction rich in oleic acid.

5 7 – Complexes according to any one of claims 1 to 6, in which the strontium cation is selected in the group consisting of the dihalogenides, more specifically strontium dichloride, sulfates, hydrates, organic strontium derivatives such as acetylacetonates, alcoholates, in particular strontium ranelate, and complexes of strontium with organic solvents.

10 8 – Pharmaceutical composition containing at least one complex such as defined in any one of claims 1 to 7 and a pharmaceutically acceptable vehicle, excipient or support.

15 9 – Use of complexes such as defined in any one of claims 1 to 7 for preparing a medicament intended for use as a regulator or stimulant of bone growth, particularly in the treatment or prevention of deficiencies or dysfunctions of bone growth, specifically in the treatment or prevention of osteoporosis.

20 10 – Use of complexes such as defined in any one of claims 1 to 7 for preparing a medicament intended to stimulate the production of hematopoietic stem cells, particularly in the treatment of blood diseases involving a hematopoietic deficit, more specifically as an adjunct to anticancer chemotherapies.

11 – Dietetic products containing at least one complex such as defined in any one of claims 1 to 7.

25 12 – Dietetic products according to the previous claim for regulating calcium metabolism and/or preventing bone deterioration (density and/or quality).